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Abstract
Granulysin is a cytolytic protein expressed in cytotoxic T and natural killer (NK) cells. Abnormal serum levels of granulysin in
lymphomas with NK and cytotoxic phenotype have been shown to correlate with tumour progression. In this study, we inves-
tigated the expression pattern of granulysin in routine sections of normal and reactive lymphoid tissues as well as in a large series
of lymphomas. In normal tissues, granulysin labelled a small population of cells that double immunostaining revealed to belong
to the pool of cytotoxic T/NK cells. Among lymphoid neoplasms, the highest expression of granulysin (71%) was found in
extranodal NK/T cell lymphomas of nasal type (ENKTL). To note is that 29% of ENKTLs, which were negative for one or more
of classical cytotoxic markers strongly expressed granulysin. Furthermore, expression of granulysin was observed in rare cases of
T cell lymphomas with a cytotoxic phenotype (i.e. ALK-negative anaplastic large cell lymphoma (26%), enteropathy-associated
T cell lymphoma (12%) and peripheral T cell lymphoma, NOS (4%)). None of the investigated non-Hodgkin B cell lymphomas,
Hodgkin lymphoma and plasma cell myeloma were granulysin positive. The results suggest granulysin as a novel marker for a
subset of cytotoxic NK cell derived malignancies and its usefulness is highlighted in those ENKTLs that lack expression of other
cytotoxic markers but retain granulysin expression.
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Introduction
Granulysin is a sposin-like lipid-binding protein that was orig-
inally described in 1998 as a human antimicrobial peptide
with a broad activity against intracellular pathogens [1]. The
protein was initially identified as a cytolytic and pro-
inflammatory molecule expressed by natural killer (NK) cells
and activated cytotoxic T lymphocytes (CTLs) [2, 3]. It is
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localised within granules and associated with other pore-
forming proteins like perforin and granzyme [1, 4].
Several studies have shown the clinical relevance of
granulysin in a number of physiologic conditions including
reproductive biology, innate immunity, dendritic cell chemo-
taxis and activation as well as in infectious diseases and in
cancers [5–7]. It has been shown that serum levels of
granulysin in patients with mature NK neoplasms were abnor-
mal and heterogeneously expressed [8]. The findings led to
suggest granulysin as a potential diagnostic and prognostic
marker for these lymphoma types [8].
Mature NK/T cell lymphomas are distinct clinicopath-
ological entities and include extranodal NK/T cell lym-
phoma, nasal type (ENKTL), aggressive NK-cell leukae-
mia (ANKL) and chronic lymphoproliferative disorders
of NK cells (CLPD-NK) [9]. ENKTL predominantly oc-
curs in Asian and Central/South American populations,
shows frequent involvement of extra-nodal sites [9–12]
though nodal localizations are described and it is associ-
ated with Epstein-Barr virus (EBV) infection [10]. The
neoplastic cells show variable expression of NK and cy-
totoxic T cell markers and molecular studies demonstrat-
ed T cell receptor (TCR) gene rearrangements only in a
minority of cases [9].
The diagnosis of ENKTL is often challenging due to the
variable morphologic and immunophenotypic features [13–15]
overlapping sometimes to those of subsets of T cell lymphomas
with cytotoxic phenotype and pathologists need additional and
robust markers to achieve precision diagnosis. Identification of a
novel marker that can help in this diagnostic setting is of interest.
In the present investigation, we carried out an immunohis-
tochemical analysis of granulysin, in normal and neoplastic
lymphoid tissues, with the aim to assess its potential utility to
refine the diagnosis of NK/T cell lymphoma subtypes.
Materials and methods
Patients and tissue samples Formalin-fixed paraffin-
embedded (FFPE) tissue blocks were retrieved from the
files of the Departments of Histopathology, University
College Hospital, London, UK; Pathology, Stanford
University School of Medicine, CA, USA; Pathology,
University Hospital of Wales, Cardiff, UK; and from the
Units of Pathology, University Hospital Siena and of
Haematopathology, S. Orsola Malpighi Hospital, University
of Bologna, Italy. In addition, sections of tissue microarrays
(TMAs) constructed from FFPE tissue samples of T cell lym-
phoma subtypes, as reported previously [16], were also in-
cluded. The tissue-microarrays were generated upon selection
of representative, tumour-rich areas by two expert
haematopathologists (YN and HM-K) and were retrieved
from the files of the Departments of Pathology, Stanford
University School of Medicine, Stanford, USA, and San
Juan General Hospital Guatemala City, Guatemala.
The samples included in this investigation consisted
of normal lymphoid tissues comprising thymus (n = 1),
tonsils (n = 4), lymph node (n = 1), spleen (n = 1), two
lymph nodes showing reactive changes specific of EBV-
associated lymphadenitis (i.e. infectious mononucleosis),
five lymph nodes with the diagnosis of chronic active
EBV infection (CAEBV), and a large series of non-
Hodgkin and Hodgkin lymphomas (Table 1).
Primary diagnosis was performed at each Institution by
expert haematopathologists according to the criteria of the
updated World Health Organization classification of Tumors
of Haematopoietic and Lymphoid Tissues [9].
IHC and antibodies Immunohistochemistry (IHC) was carried
out on a Bond-III Autostainer (Leica Microsystems,
Newcastle upon Tyne, UK) as previously described [17].
The following mouse monoclonal antibodies raised against
fixation-resistant epitopes were applied: anti-granulysin
(clone F-9, dilution 1:300, Santa Cruz, Santa Cruz
Biotechnology, Inc., TX, USA), anti-CD3 (clone LN10, dilu-
tion 1:100, Leica Microsystems Ltd., Newcastle-upon-Tyne,
UK), anti-CD5 (clone 4C7; dilution 1:100, Leica
Table 1 Expression of granulysin in haematological neoplasms
Lymphoma/leukaemia entity n/N (%)
B cell lymphoma Chronic lymphocytic leukaemia 0/10
Mantle cell lymphoma 0/10
Follicular lymphoma 0/10
Diffuse large B cell lymphoma 0/10
T-cell/histiocyte-rich large B cell lymphoma 0/7
Burkitt lymphoma 0/9
Hairy cell leukaemia 0/7
Chronic active EBV infection
(CAEBV), B cell type
0/1
T/NK cell
lymphoma
Extranodal NK/T cell lymphoma,
nasal type
61/86
(71%)
ALK-negative anaplastic large cell lymphoma
(ALK-ALCL)
4/15
(26%)
Enteropathy-associated T-cell lymphoma
(EATL)
1/8
(12%)
Peripheral T-cell lymphoma, NOS
(PTCL, NOS)
2/50
(4%)
T-cell large granular lymphocytic leukaemia 0/8
Angioimmunoblastic T-cell lymphoma 0/24
ALK-positive anaplastic large cell lymphoma
(ALK+ALCL)
0/5
Hepatosplenic T-cell lymphoma 0/8
T-lymphoblastic leukaemia (T-ALL) 0/6
Adult T cell leukaemia/lymphoma (ATLL) 0/6
CAEBV, T cell type 0/4
Hodgkin
lymphoma
Classical 0/20
Lymphocyte predominant 0/29
Plasma cells
neoplasms
Myeloma 0/10
n number of cases positive for granulysin, N total number of cases, %
percentage of positive cases, NOS not otherwise specified
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Microsystems Ltd., Newcastle-upon-Tyne, UK), anti-CD2
(clone 11F11, dilution RTU, Leica Microsystems Ltd.,
Newcastle-upon-Tyne, UK), anti-CD7 (clone LP15, dilution
RTU, Leica Microsystems Ltd., Newcastle-upon-Tyne, UK),
anti-CD4 (clone 4B12, dilution RTU, Leica Microsystems
Ltd., Newcastle-upon-Tyne, UK), anti-CD8 (clone 4B11, di-
lution RTU, Leica Microsystems Ltd., Newcastle-upon-Tyne,
UK), anti-CD30 (clone JCM182, dilution RTU, Leica
Microsystems Ltd., Newcastle-upon-Tyne, UK), anti-CD43
(clone MT1, dilution RTU, Leica Microsystems Ltd.,
Newcastle-upon-Tyne, UK), anti-CD56 (clone CD564, dilu-
tion RTU, Leica Microsystems Ltd., Newcastle-upon-Tyne,
UK), anti-granzyme B (clone 11F1, dilution RTU, Leica
Microsystems Ltd., Newcastle-upon-Tyne, UK), anti-TIA-1
(clone 2G9A10F5, dilution 1:150, Beckman Coulter Ltd.,
High Wycombe, UK), anti-perforin (clone 5B10, dilution
1:30, Leica Microsystems Ltd., Newcastle-upon-Tyne, UK).
To investigate the expression pattern of granulysin in lym-
phoid cell subsets, sections of reactive tonsil and lymph node
as well as lymph node of patients with infectious mononucle-
osis were analysed to double immunostaining using a protocol
described elsewhere [18]. The antibodies panels consisted of
granulysin in combination with one of the following mole-
cules: CD4, CD8, CD56 and granzyme B.
In ENKTL cases staining for CD56, granzyme B, TIA1
and perforin was assessed as percentage of positive tumour
cells over the total number of cells.
The review and scoring of the staining was performed by
expert haematopathologists (GLB, MRA, LL, YN and TM)
who were blinded to each other and to the clinical history and
original diagnosis.
The score to assess the percentage of positive cells
over the number of all cells was set as it follows: 1
(10–25% positive cells), 2 (25–75% positive cells) and
3 (> 75% positive cells) [19].
Five different fields (at least 100 cells/field) were
evaluated at × 200 magnification. Cases with discrepant
scoring were reviewed jointly by two out of the four
haematopathologists to reach a final consensus.
Detection of EBV In situ hybridization for detection of the
EBV-encoded small RNAs (EBER) was performed using
the INFORM EBER Probe (Ventana/ROCHE, Tucson,
AZ, US). The technique was carried out in the
Fig. 1 Expression of granulysin
in normal lymphoid tissues.
Tonsil (a, b), lymph node (c, d),
spleen (e, f) [a, c, e original
magnification (O.M.): × 10; b, d,
f O.M. × 20]
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BenchMark Ultra (Ventana/ROCHE) platform according
to the manufacturer’s instructions, as previously de-
scribed [20].
Statistical analysis Chi-square test (99% CI) and GraphPad
Software (La Jolla, CA, USA) were used to calculate the p
value in the statistical analysis.
Results
Granulysin expression in non-neoplastic lymphoid
tissues
Granulysin showed a membranous and intracellular (dot-like)
staining restricted to a small population of cells in the
interfollicular areas of reactive tonsils and lymph nodes
(Fig. 1). In the red pulp of the spleen and in the medulla of
the thymus, scattered granulysin-positive cells were seen (Fig.
1). Double immunostaining carried out in tissue sections of
reactive tonsil and lymph node demonstrated that the
granulysin-positive cells were mostly CD4 negative and few
co-expressed CD8. The majority of granulysin-positive cells
co-expressed CD56 (Fig. 2).
B cells, plasma cells, macrophages, epithelioid histiocytes
and dendritic cells were granulysin negative.
Granulysin expression in CAEBV
Five lymph nodes with the diagnosis of CAEBV were includ-
ed in this study. All cases showed EBV infection by EBER-
ISH and strongly expressed one or more of the following
markers: CD2, CD3, CD8, TIA-1, granzyme B and perforin.
Four out of five cases were T cell type CAEBV (also con-
firmed by PCR detection of a monoclonal TCR rearrange-
ment), and the remaining case was of B cell type.
Only scattered lymphocytes, expressing one or more cyto-
toxic markers, were granulysin positive.
Granulysin expression in haematological
malignancies
Table 1 summarises the results of granulysin in a series of
haematological malignancies.
Granulysin was found to be mainly restricted to some
NK/T cell lymphoma subtypes, and the highest expres-
sion was observed in ENKTLs (61/86; 71%). All the
investigated ENKTL cases were EBER-positive and
strongly expressed one or more of the cytotoxic markers
(i.e. CD56, granzyme B, TIA-1 and perforin) and/or
CD2, CD3, CD7 and CD43 (Table 2).
The intensity of granulysin in the 61 positive
ENKTLs was strong and comparable to that of the other
cytotoxic markers, and in each case, more than 75% of
tumour cells were positive (score 3, Fig. 3). To note is
that 26 out of the 61 granulysin-positive cases showed a
statistically significant lower level of expression of the
other cytotoxic markers (p < 0.01) whereas granulysin
was homogeneous and strong in all instances. Table 3
summarises the clinicopathological data of the 26 cases
with strong granulysin expression and lack of one or all
others cytotoxic markers (Figs. 4 and 5).
Fig. 2 Double immunostaining of
granulysin and T/NK cell markers
in reactive tonsils. CD4-positive
cells are granulysin negative (a); a
few CD8-positive cells co-
expressed granulysin (b). The
majority of CD56-positive cells
were granulysin positive (c). In all
images, granulysin is in blue with
the exception in b which is in
brown. No counterstaining is
performed. [O.M.: a– c × 20]
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In the remaining 25 ENKTL cases (29%), the neo-
plastic cells were consistently granulysin negative; the
clinicopathological data of these cases are detailed in
Table 4. We may conclude that the majority of
granulysin-negative ENKTCL cases lack expression of
perforin. Moreover, all granulysin-negative cases arose
from upper digestive tract (nasal cavity, nasopharynx,
paranasal sinus and palate) while many strongly
granulysin-positive cases are from skin, testis and gas-
trointestinal tract (stomach, small intestine and large
bowel).
Furthermore, weak granulysin positivity (score 1) was seen
in 4 out of 15 (26%) ALK-negative anaplastic large cell lym-
phomas (ALK-ALCL), 1 out of 8 (12%) enteropathy-
associated T cell lymphomas (EATL, all cases are type I)
Table 2 Immunohistochemical and in situ hybridization results in
nasal-type extranodal NK/T cell lymphomas
Marker Positivity (n/N)
Granulysin 71% (61/86)
CD56 98,8% (85/86)
Granzyme B 77% (66/86)
TIA-1 68% (59/86)
Perforin 40% (34/86)
EBER 100% (86/86)
CD2 86% (49/57)
CD3 (cytoplasmic) 76% (65/86)
CD7 75% (6/8)
CD43 100% (42/42)
CD5 3,6% (2/56)
CD30 16% (7/43)
n number of cases positive for granulysin, N total number of cases, %
percentage of positive cases
Fig. 3 Granulysin ENKTL
lymphomas with different organs
involvement. Nasal cavity (a, b),
rete testis (c, d), skin (e, f) [a, c
O.M. × 10; e O.M. × 2.5; b, d, f
O.M. × 20]
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and 2 out of 50 (4%) peripheral T cell lymphomas, NOS
(PTCL, NOS), both showing gamma/delta genotype.
All cases of non-Hodgkin B cell lymphoma, Hodgkin lym-
phoma and plasma cell myeloma were granulysin negative.
Discussion
Expression of granulysin in normal and neoplastic lym-
phoid tissues has been only rarely characterised [8]. In
the current study, we show that granulysin is expressed
in cytotoxic/NK lymphocytes and in subsets of NK/T
cell derived lymphomas.
In normal tissues, granulysin marked small numbers of T/
NK-cells within the interfollicular areas of tonsils, lymph
nodes and in the red pulp of the spleen. These findings
correlate with a previous report describing the expression of
granulysin in cytotoxic NK/T cells [4].
Our findings showed that the majority of granulysin-
positive cells co-expressed CD56 while most of the
CD4+ and CD8+ T cells were negative for granulysin.
This suggests that the expression of granulysin is main-
ly restricted to NK cells and derived neoplasms.
Accordingly, we found that the highest level (score 3)
of granulysin expression was in a subset of ENKTLs
(71%) and higher when compared to that of other cyto-
toxic markers (p < 0.01). This finding supported the re-
sults of a previous investigation that reported elevated
serum levels of granulysin in patients with NK/T cell
lymphoma [8]. In the present study, we are not able to
quantify serum levels of granulysin from blood samples
and to correlate with its expression in tumour tissue.
The importance of this analysis was pointed out in a
Table 3 Immunohistochemical features of granulysin-positive ENKTL cases with lower level of expression of the other cytotoxic markers
Case Site Age Sex CD56 Granzyme
B
TIA-
1
Perforin cCD3 CD4 CD8
1 Nasal cavity 22 M Pos Neg Neg Neg Pos Neg Neg
2 Nasopharynx 54 M Pos Neg Neg Neg Pos Neg Neg
3 BM 51 M Pos Neg Pos Neg Pos Neg Neg
4 Stomach 74 M Pos Neg Neg Pos Pos Neg Neg
5 Maxilla 28 M Pos Pos Neg Neg Pos Neg Neg
6 Duodenum 56 M Pos Pos Neg Neg Neg Neg Neg
7 Soft palate 23 F Pos Pos Neg Neg Pos Neg Pos
8 Nasopharynx 37 M Pos Neg Pos Neg Pos Neg Neg
9 Nasal
septum
17 F Pos Neg Pos Neg Pos Neg Neg
10 Nasal cavity 50 F Pos Pos Neg Neg Pos Neg Neg
11 Soft palate 35 F Pos Pos Neg Neg Pos Neg Neg
12 Nasal
septum
8 M Pos Pos Neg Neg Pos Neg Neg
13 Palate 61 F Pos Neg Pos Neg Pos Neg Pos
14 Skin/breast 40 F Pos Pos Pos Neg Pos Neg Neg
15 Stomach 24 M Pos Pos Pos Neg Neg Neg Neg
16 Nasal fossa 51 M Pos Pos Pos Neg Pos Neg Neg
17 Nasal
septum
38 F Pos Pos Pos Neg Pos Neg Neg
18 Nasopharynx 42 F Pos Pos Pos Neg Pos Neg Neg
19 Skin 48 M Pos Pos Pos Neg Pos Neg Neg
20 Maxilla 60 M Pos Pos Pos Neg Pos Neg Neg
21 Caecum 26 F Pos Pos Neg Pos Pos Neg Neg
22 Testicle 18 M Pos Pos Pos Neg Pos Neg Neg
23 Testis 51 M Pos Neg Neg Neg Pos Neg Neg
24 Skin 24 M Pos Pos Neg Pos Neg Neg Neg
25 Nasal fossa 44 F Pos Pos Pos Neg Pos Neg Neg
26 Large bowel 80 M Pos Neg Pos Neg Pos Neg Neg
All cases were granulysin and EBER positive. TCR rearrangement is not available in all cases but not two (n 3 and 24) that are polyclonal
Pos positive, Neg negative, M male, F female, BM bone marrow, cCD3 cytoplasmic CD3
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previous investigation being an indicator of disease bur-
den. A significant higher serum level found in ANKL
than in ENKTL correlated with increased cancer cells
load in the NK cell leukaemia [8]. In fact, serum levels
of granulysin significantly decreased after treatment,
suggesting its potential role as prognostic marker [8].
The staining pattern of granulysin was comparable to that
of commonly used cytotoxic markers granzyme B, TIA-1 and
perforin, thus suggesting its diagnostic usefulness in the clin-
ical setting of ENKTLs. This was further highlighted by
strong granulysin positivity observed in a proportion of
ENKTLs (30%) that lacked expression of one or more of the
classical cytotoxic markers.
Our results showing granulysin expression in a small pro-
portion of other lymphomas with cytotoxic phenotypes, i.e.
ALK-negative ALCL, EATL and PTCL NOS support previ-
ous observations of granulysin positivity in systemic ALCL of
childhood, in mycosis fungoides (MF) and Sézary syn-
drome [21, 22]. However, both studies did not give
details regarding the number of investigated cases and
incidence of granulysin positivity or staining pattern
characteristics. In our analysis, we found that in adult
Fig. 4 Granulysin is strongly
expressed in tumour cells of
ENKTL cases that lack other
cytotoxic markers. a Granulysin,
b granzyme B, c TIA-1, d
perforin. In the first case, tumour
cells are negative for granzyme B
and perforin but they express
weakly TIA-1. [O.M. a–d × 40]
Fig. 5 Granulysin is strongly
expressed in tumour cells of
ENKTL cases that lack other
cytotoxic markers. a Granulysin,
b granzyme B, c TIA-1, d
perforin. In the second case,
tumour cells are negative for TIA-
1 and perforin but they express
weakly granzyme B [O.M. a–d ×
40]
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ALK-negative ALCLs, the expression of granulysin was
less strong and intense than in ENKTL cases and in
addition restricted to a small proportion of tumour cells
(less than 25%; score 1).
Although we found granulysin expression in the ma-
jority of ENKTCL cases, further experiments with NK
and cytotoxic T cell lines are required to demonstrate
granulysin as a cytotoxic marker of NK cells and de-
rived lymphomas and to correlate with cell of origin
(NK versus T cell).
Finally, it should be mentioned that granulysin may
represent a potential therapeutic target for NK/T cell
lymphomas that are characterised by a poor prognosis
[5]. Notoriously, successful disease control is rarely
achieved in most ENKTL patients with relapsed or re-
fractory diseases, and consistent with several interna-
tional clinicopathological studies [23], the treatment of
ENKTL nasal type differs according to the stage of the
disease. Patients with systemic disease tend to be treated
with L-asparaginase-containing regimens and although
showed best results, toxicity is not negligeable [23].
Thus, development of tailored drugs targeted to novel
biomarkers, and granulysin might represent one, should
be considered in order to improve treatment outcome.
In conclusion, our study suggests granulysin as an
additional molecule for cytotoxic and NK/T cells as well
as a reliable diagnostic marker for NK/T cell-derived
lymphoma subtypes and useful for those ENKTLs that
lack expression of one or more of the commonly used
cytotoxic markers.
Our results open new insights for future investigations
aimed to validate the clinical value of granulysin to monitor
disease in biopsies post-therapy.
Author’s contributions TM, LL and SAP conceived and designed the
study; GLB,MRA,MP, SD, SAP, LL and TMwrote, edited and reviewed
the manuscript. GLB, AUA, YN, AC, ES, MDL, HMK, SZ, AR and
MRG researched and analysed data. All authors gave final approval for
publication. TM takes full responsibility for the work as a whole, includ-
ing the study design, access to data and the decision to submit and publish
the manuscript.
Table 4 Immunohistochemical features of granulysin-negative ENKTL cases
Case Site Age Sex CD56 Granzyme B TIA-
1
Perforin cCD3 CD4 CD8
1 Nasal cavity 41 M Pos Pos Pos Neg Pos Neg Neg
2 Palate 65 F Pos Neg Pos Neg Pos Neg Neg
3 Palate 47 M Pos Pos Neg Neg Pos Neg Pos (weak)
4 Nasal fossa 53 M Pos Pos Pos Neg Pos Neg Neg
5 Nasal fossa 58 F Pos Neg Pos Neg Pos Neg Neg
6 Nasal fossa 54 M Pos Pos Neg Neg Pos Neg Neg
7 Nasal sinus 45 M Pos Pos Pos Neg Pos Neg Neg
8 Nasal sinus 44 F Pos Pos Pos Neg Pos Neg Neg
9 Lymph node 51 F Pos Pos Pos Pos Pos Neg Neg
10 BM 52 M Pos Pos Pos Pos Pos Neg Neg
11 Palate 35 M Pos Neg Pos Neg Pos Neg Neg
12 Nasal cavity 42 M Pos Pos Pos Neg Pos Neg Neg
13 Nasal cavity 61 F Pos Neg Pos Pos Neg Neg Neg
14 Nasal cavity 54 M Pos Pos Pos Neg Pos Neg Neg
15 Oral cavity 63 F Pos Pos Pos Pos Pos Neg Neg
16 Palate 47 M Pos Pos Pos Neg Pos Neg Neg
17 Palate 52 M Pos Pos Neg Neg Pos Neg Neg
18 Nasal cavity 48 F Pos Pos Neg Neg Pos Neg Neg
19 Maxilla 41 M Pos Pos Pos Neg Pos Neg Neg
20 Lymph node 60 M Pos Pos Pos Neg Pos Neg Neg
21 Nasal cavity 53 M Pos Pos Pos Pos Pos Neg Neg
22 Nasal fossa 49 F Pos Pos NA NA Pos Neg Neg
23 Nasal cavity 41 M Pos Pos NA NA Pos Pos (focal) Neg
24 Nasal cavity 57 F Pos Pos Pos NA Pos Neg Pos
25 Nasal cavity 54 M Pos Pos Pos NA Pos Neg Pos
All cases were EBER positive and granulysin negative. TCR rearrangement is not available in all cases but not one (n 11) that is polyclonal
Pos positive, Neg negative, NA not available, M male, F female, BM bone marrow
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